Progress in novel monoclonal antibodies in the treatment of diffuse large B-cell lymphoma

Liu Chen; Lü Qing

doi:10.13406/j.cnki.cyxb.003215

您当前的位置：

首页 >

文章列表页 >

Progress in novel monoclonal antibodies in the treatment of diffuse large B-cell lymphoma

Literature review | 更新时间：2025-10-21

- Progress in novel monoclonal antibodies in the treatment of diffuse large B-cell lymphoma
- Journal of Chongqing Medical University Vol. 48, Issue 4, Pages: 488-494(2023)
- 作者机构：
  
  1.重庆医科大学附属第一医院血液内科，重庆 400016
  2.重庆市人民医院医学研究中心，重庆 400030
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003215
  CLC： R551.2
- Received：10 June 2022，
  
  Revised：2022-09-15，
  
  Accepted：27 February 2023，
  
  Published：28 April 2023
- 稿件说明：
移动端阅览
吕青,王欣.抗体靶向治疗在弥漫性大B细胞淋巴瘤中的研究进展[J].重庆医科大学学报,2023,48(4):488-494.

Chen Liu,Qing Lü.Progress in novel monoclonal antibodies in the treatment of diffuse large B-cell lymphoma[J].Journal of Chongqing Medical University,2023,48(4):488-494.
吕青,王欣.抗体靶向治疗在弥漫性大B细胞淋巴瘤中的研究进展[J].重庆医科大学学报,2023,48(4):488-494. DOI： 10.13406/j.cnki.cyxb.003215.

Chen Liu,Qing Lü.Progress in novel monoclonal antibodies in the treatment of diffuse large B-cell lymphoma[J].Journal of Chongqing Medical University,2023,48(4):488-494. DOI： 10.13406/j.cnki.cyxb.003215.

摘要

弥漫性大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）是一种侵袭性淋巴瘤，通常采用含CD20单克隆抗体（利妥昔单抗）的免疫化疗方案，然而仍有部分复发难治（relapsed/refractory，R/R）患者无法获得临床治愈。近年来，不少新开发的单抗类药物用于治疗DLBCL，显著改善了R/R DLBCL的预后。本综述系统讨论这些单抗类药物，包括传统简单结构的单克隆抗体、双特异性抗体（bispecific antibodies，bsAb）及抗体-药物偶联物（antibody-drug conjugates，ADCs）。首先介绍除利妥昔单抗以外的其他传统单抗，主要涉及单抗结构上的改进及针对更多的靶点。接着详细阐述bsAb的基本结构和作用机制，以及各种不同双抗结合位点带来的多种可能及尝试。最后对ADCs的作用机制及结构各部分做详细的分析比较。文中还介绍这些单抗类药物用于治疗DLBCL的最新临床试验数据，包括反应率、无进展生存期等疗效结果，以及主要的不良反应。

Abstract

Diffuse large B-cell lymphoma（DLBCL） is an aggressive lymphoma usually treated with CD20 monoclonal antibodies （mAb），rituximab in combination with chemotherapy. However，there are still some relapsed/refractory（R/R） patients who cannot be cured. In recent years，many novel monoclonal antibodies have been developed to treat DLBCL，which has significantly improved the prognosis of R/R DLBCL. In this review，we systematically discuss these mAb，including traditional mAb，bispecific antibodies （bsAb），and antibody-drug conjugates（ADCs）. Firstly，other traditional mAb rather than rituximab are introduced in this review， mainly involving the improvement of monoclonal antibody structure and targeting more targets. Then，we elaborate the basic structure and mechanism of bsAb，as well as various possibilities brought by various combination from different binding sites. Finally，the mechanism and structure of ADCs are analyzed and compared in detail. The article also reviews the latest clinical trial data of these antibodies in treatment of DLBCL，including response rates，progression-free survival and other efficacy results，as well as major adverse reactions.

关键词

Keywords

references

Chow VA ， Shadman M ， Gopal AK . Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma [J ] . Blood ， 2018 ， 132 （ 8 ）： 777 - 781 .

Papageorgiou SG ， Thomopoulos TP ， Katagas I ， et al . Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications [J ] . Ther Adv Hematol ， 2021 ， 12 ： 20406207211013987 .

Kambhampati S ， Hunter B ， Varnavski A ， et al . Ofatumumab，etoposide，and cytarabine intensive mobilization regimen in patients with high-risk relapsed/refractory diffuse large B-cell lymphoma undergoing autologous stem cell transplantation [J ] . Clin Lymphoma Myeloma Leuk ， 2021 ， 21 （ 4 ）： 246 - 256 . e2.

van Imhoff GW ， McMillan A ， Matasar MJ ， et al . Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma：the ORCHARRD study [J ] . J Clin Oncol ， 2017 ， 35 （ 5 ）： 544 - 551 .

O'Nions J ， Townsend W . The role of obinutuzumab in the management of follicular lymphoma [J ] . Future Oncol ， 2019 ， 15 （ 31 ）： 3565 - 3578 .

Sehn LH ， Martelli M ， Trněný M ， et al . A randomized，open-label，Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma：final analysis of GOYA [J ] . J Hematol Oncol ， 2020 ， 13 （ 1 ）： 71 .

Makita S ， Tobinai K . Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma [J ] . Ann Oncol ， 2018 ， 29 （ 5 ）： 1086 - 1089 .

Düll J ， Topp M ， Salles G . The use of tafasitamab in diffuse large B-cell lymphoma [J ] . Ther Adv Hematol ， 2021 ， 12 ： 20406207211027458 .

Salles G ， Duell J ， González Barca E ， et al . Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma （L-MIND）：a multicentre，prospective，single-arm，phase 2 study [J ] . Lancet Oncol ， 2020 ， 21 （ 7 ）： 978 - 988 .

Voso MT ， Falconi G ， Fabiani E . What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms [J ] . Blood ， 2021 ， 138 （ 9 ）： 749 - 757 .

Chao MP ， Takimoto CH ， Feng DD ， et al . Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies [J ] . Front Oncol ， 2019 ， 9 ： 1380 .

Advani R ， Flinn I ， Popplewell L ， et al . CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma [J ] . N Engl J Med ， 2018 ， 379 （ 18 ）： 1711 - 1721 .

Balzarotti M ， Magagnoli M ， Canales MÁ ， et al . A phase Ib，open-label，dose-escalation trial of the anti-CD37 monoclonal antibody，BI 836826，in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma [J ] . Invest New Drugs ， 2021 ， 39 （ 4 ）： 1028 - 1035 .

Coloma MJ ， Morrison SL . Design and production of novel tetravalent bispecific antibodies [J ] . Nat Biotechnol ， 1997 ， 15 （ 2 ）： 159 - 163 .

Kufer P ， Lutterbüse R ， Baeuerle PA . A revival of bispecific antibodies [J ] . Trends Biotechnol ， 2004 ， 22 （ 5 ）： 238 - 244 .

Wang SH ， Chen K ， Lei Q ， et al . The state of the art of bispecific antibodies for treating human malignancies [J ] . EMBO Mol Med ， 2021 ， 13 （ 9 ）： e14291 .

Curran E ， O'Brien M . Role of blinatumomab，inotuzumab，and CAR T-cells：which to choose and how to sequence for patients with relapsed disease [J ] . Semin Hematol ， 2020 ， 57 （ 3 ）： 157 - 163 .

Coyle L ， Morley NJ ， Rambaldi A ， et al . Open-Label，phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma [J ] . Leuk Lymphoma ， 2020 ， 61 （ 9 ）： 2103 - 2112 .

Viardot A ， Hess G ， Bargou RC ， et al . Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma [J ] . Leuk Lymphoma ， 2020 ， 61 （ 11 ）： 2767 - 2770 .

Dufner V ， Sayehli CM ， Chatterjee M ， et al . Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab [J ] . Blood Adv ， 2019 ， 3 （ 16 ）： 2491 - 2498 .

Poh C ， Frankel P ， Ruel C ， et al . Blinatumomab/lenalidomide in relapsed/refractory non-Hodgkin's lymphoma：a phase I California cancer consortium study of safety，efficacy and immune correlative analysis [J ] . Blood ， 2019 ， 134 ： 760 .

Schuster SJ ， Bartlett NL ， Assouline S ， et al . Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients，including those who are resistant to or relapsing after chimeric antigen receptor T-cell（CAR-T）therapies，and is active in treatment through multiple lines [J ] . Blood ， 2019 ， 134 ： 6 .

Matasar Matthew J ， Yoon CC ， Hyun YD ， et al . Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma：promising safety and encouraging efficacy in dose escalation cohorts [J ] . Blood ， 2020 ， 136 （ Suppl 1 ）： 45 - 46 .

Olszewski AJ ， Avigdor A ， Babu S ， et al . Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma [J ] . Blood ， 2020 ， 136 ： 43 - 45 .

Phillips Tycel J ， Olszewski Adam J ， Javier M ， et al . Mosunetuzumab，a novel CD20/CD3 bispecific antibody，in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma [J ] . Blood ， 2020 ， 136 （ Suppl 1 ）： 37 - 38 .

Martin H ， Carmelo CS ， Emmanuel B ， et al . Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma [J ] . Blood ， 2020 ， 136 （ Suppl 1 ）： 46 - 48 .

Rajat B ， Allan John N ， Arnason Jon E ， et al . Odronextamab（REGN1979），a human CD20 × CD3 bispecific antibody，induces durable，complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma，including patients refractory to CAR T therapy [J ] . Blood ， 2020 ， 136 （ Suppl 1 ）： 42 - 43 .

Hutchings M ， Mous R ， Clausen MR ， et al . Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes，including patients with prior CAR-T therapy：updated dose escalation data [J ] . Blood ， 2020 ， 136 ： 45 - 46 .

Schuster SJ . Bispecific antibodies for the treatment of lymphomas：promises and challenges [J ] . Hematol Oncol ， 2021 ， 39 （ Suppl 1 ）： 113 - 116 .

Morschhauser F ， Flinn IW ， Advani R ， et al . Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma：final results from a phase 2 randomised study（ROMULUS） [J ] . Lancet Haematol ， 2019 ， 6 （ 5 ）： e254 - e265 .

Sehn LH ， Herrera AF ， Flowers CR ， et al . Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma [J ] . J Clin Oncol ， 2020 ， 38 （ 2 ）： 155 - 165 .

Giuseppe G ， Paula M ， Phillips Tycel J ， et al . Polatuzumab vedotin plus venetoclax with rituximab in relapsed/refractory diffuse large B-cell lymphoma：primary efficacy analysis of a phase Ⅰb /Ⅱ study [J ] . Blood ， 2020 ， 136 （ Suppl 1 ）： 45 - 47 .

Tilly H ， Morschhauser F ， Bartlett NL ， et al . Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma：an open-label，non-randomised，phase 1b-2 study [J ] . Lancet Oncol ， 2019 ， 20 （ 7 ）： 998 - 1010 .

Hamadani M ， Radford J ， Carlo-Stella C ， et al . Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma [J ] . Blood ， 2021 ， 137 （ 19 ）： 2634 - 2645 .

Caimi Paolo F ， Z Ai WY ， Pablo AJ ， et al . Efficacy and safety of loncastuximab tesirine （ADCT-402） in relapsed/refractory diffuse large B-cell lymphoma [J ] . Blood ， 2020 ， 136 （ Suppl 1 ）： 35 - 37 .

Dang NH ， Ogura M ， Castaigne S ， et al . Randomized，phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma [J ] . Br J Haematol ， 2018 ， 182 （ 4 ）： 583 - 586 .

Hernandez-Ilizaliturri Francisco J ， Flinn Ian W ， John K ， et al . A phase I pharmacokinetic（PK）and safety study of trph-222 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma（R/R NHL）：dose-escalation results [J ] . Blood ， 2020 ， 136 （ Suppl 1 ）： 41 - 42 .

Shea L ， Mehta-Shah N . Brentuximab vedotin in the treatment of peripheral T cell lymphoma and cutaneous T cell lymphoma [J ] . Curr Hematol Malig Rep ， 2020 ， 15 （ 1 ）： 9 - 19 .

Makita S ， Maruyama D ， Tobinai K . Safety and efficacy of brentuximab vedotin in the treatment of classic Hodgkin lymphoma [J ] . Onco Targets Ther ， 2020 ， 13 ： 5993 - 6009 .

Bartlett NL ， Yasenchak CA ， Ashraf KK ， et al . Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma（DLBCL） [J ] . Hematol Oncol ， 2021 ， 39 （ Suppl 2 ）： 14 .

Zinzani PL ， Santoro A ， Gritti G ， et al . Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma：efficacy and safety from the phase Ⅱ CheckMate 436 study [J ] . J Clin Oncol ， 2019 ， 37 （ 33 ）： 3081 - 3089 .

Svoboda J ， Bair SM ， Landsburg DJ ， et al . Brentuximab vedotin in combination with rituximab，cyclophosphamide，doxorubicin，and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas [J ] . Haematologica ， 2021 ， 106 （ 6 ）： 1705 - 1713 .

Trnĕný M ， Verhoef G ， Dyer MJ ， et al . A phase Ⅱ multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine（SAR3419）in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy [J ] . Haematologica ， 2018 ， 103 （ 8 ）： 1351 - 1358 .

Fanale MA ， Hamlin PA ， Park SI ， et al . Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory（R/R）B-cell non-Hodgkin lymphoma（NHL）in a phase I study [J ] . J Clin Oncol ， 2018 ， 36 （ Suppl 15 ）： 7580 .

Burnett C ， Strack T ， Lehner T ， et al . A phase 2a open-label study to investigate safety and tolerability（including the MTD），efficacy，pharmacokinetics，pharmacodynamics and immunogenicity of MT-3724 in combination with gemcitabine and oxaliplatin in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma [J ] . Blood ， 2019 ， 134 ： 5322 .

Kozako T ， Aikawa A ， Ohsugi T ， et al . High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor [J ] . Eur J Pharmacol ， 2019 ， 865 ： 172738 .

Dondapati SK ， Stech M ， Zemella A ， et al . Cell-free protein synthesis：a promising option for future drug development [J ] . BioDrugs ， 2020 ， 34 （ 3 ）： 327 - 348 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Preparation and purification of anti-human epididymis protein-4 monoclonal antibody and its application in lateral flow immunoassay

Prokaryotic expression and preparation of antibody of human neutrophil gelatinase-associated lipocalin

MORPHOLOGICAL AND IMMUNOPHENOTYPICSTUDIES ON ACUTE LEUKEMIA

Effects of anti-human augmenter of liver regeneration monoclonal antibody on proliferation of HepG2 cells in vitro

In vivo selection of respiratory syncytial viruses resistant to monoclonal antibody prophylaxis

Related Author

Chen Chunxia

Wang Zhizeng

Wu Jinbo

Xue Menghan

Yang Zhan

Wang Deqiang

Niu Siqiang

Yang Yuan

Related Institution

Department of Laboratory Medicine，School of Medicine，Chongqing University

Joint National Laboratory for Antibody Drug Engineering，Henan University

Key Laboratory of Molecular Biology on Infectious Diseases Established by Ministry of Education

Department of Clinical Laboratory，The First Affiliated Hospital of Chongqing Medical University

Key Laboratory of Clinical Laboratory Diagnosis，College of Laboratory Medicine，Chongqing Medical University

⁰